Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series

Inge L Sarens, Ingele Casteels, Jordi Anton, Brigitte Bader-Meunier, Philippe Brissaud, Gaelle Chédeville, Rolando Cimaz, Andrew D Dick, Graciella Espada, Jorge Fernandez-Martin, Catherine M Guly, Eric Hachulla, Miroslav Harjacek, Raju Khubchandani, Friederike Mackensen, Rosa Merino, Consuelo Modesto, Antonio Naranjo, Sheila Oliveira-Knupp, Seza ÖzenChristine Pajot, Athimalaipet V Ramanan, Ricardo Russo, Gordana Susic, Akaluck Thatayatikom, Caroline Thomée, Sebastiaan Vastert, John Bertin, Juan I Arostegui, Carlos D Rose, Carine H Wouters

Research output: Contribution to journalArticle (Academic Journal)peer-review

54 Citations (Scopus)
377 Downloads (Pure)


PURPOSE: Provide baseline and preliminary follow-up results in a 5-year longitudinal study of Blau syndrome.

DESIGN: Multicenter, prospective interventional case series.

METHODS: Baseline data from 50 patients from 25 centers worldwide, and follow-up data for patients followed 1, 2, or 3 years at the end of study enrollment. Ophthalmic data were collected at baseline and yearly visits by means of a standardized collection form.

RESULTS: Median age at onset of eye disease was 60 months and duration of eye disease at baseline 145 months. At baseline 38 patients (78%) had uveitis, which was bilateral in 37 (97%). Eight patients (21%) had moderate to severe visual impairment. Panuveitis was found in 38 eyes (51%), with characteristic multifocal choroidal infiltrates in 29 eyes (39%). Optic disc pallor in 9 eyes (12%) and peripapillary nodules in 9 eyes (12%) were the commonest signs of optic nerve involvement. Active anterior chamber inflammation was noted in 30 eyes (40%) at baseline and in 16 (34%), 17 (57%), and 11 (61%) eyes at 1, 2, and 3 years, respectively. Panuveitis was associated with longer disease duration. At baseline, 56 eyes (75%) were on topical corticosteroids. Twenty-six patients (68%) received a combination of systemic corticosteroids and immunomodulatory therapy.

CONCLUSIONS: Blau uveitis is characterized by progressive panuveitis with multifocal choroiditis, resulting in severe ocular morbidity despite continuous systemic and local immunomodulatory therapy. The frequency and severity of Blau uveitis highlight the need for close ophthalmologic surveillance as well as a search for more effective therapies.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Early online date6 Sept 2017
Publication statusE-pub ahead of print - 6 Sept 2017


  • Journal Article


Dive into the research topics of 'Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series'. Together they form a unique fingerprint.

Cite this